Heron Therapeutics Inc (NASDAQ:HRTX)’s traded shares stood at 4.67 million during the last session, with the company’s beta value hitting 1.64. At the close of trading, the stock’s price was $1.71, to imply an increase of 1.79% or $0.03 in intraday trading. The HRTX share’s 52-week high remains $3.93, putting it -129.82% down since that peak but still an impressive 39.18% since price per share fell to its 52-week low of $1.04.
Analysts have given a consensus recommendation of Buy for Heron Therapeutics Inc (HRTX), translating to a mean rating of 1.00. Of 2 analyst(s) looking at the stock, 0 analyst(s) give HRTX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.03.
Heron Therapeutics Inc (NASDAQ:HRTX) trade information
After registering a 1.79% upside in the last session, Heron Therapeutics Inc (HRTX) has traded red over the past five days. The 5-day price performance for the stock is 1.18%, and -5.52% over 30 days. With these gigs, the year-to-date price performance is 11.76%.
The extremes give us $5 and $9 for target low and target high price respectively. As such, HRTX has been trading -426.32% off suggested target high and -192.4% from its likely low.
Heron Therapeutics Inc (HRTX) estimates and forecasts
The rating firms project that company’s revenue will grow 10.88% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is 37.37M. Meanwhile, for the current quarter, a total of 1 analyst(s) estimate revenue growth to 34.25M.Earnings reports from the last fiscal year show that sales brought in 34.23M and 34.67M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 9.15% before dropping -1.21% in the following quarter.
HRTX Dividends
Heron Therapeutics Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Heron Therapeutics Inc (NASDAQ:HRTX)’s Major holders
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 8.62 million shares, or about 5.6984% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $30.16 million.
